- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Rilonacept Regeneron has been withdrawn at the request of the marketing-authorisation holder.
Rilonacept Regeneron : EPAR - Summary for the public
English (EN) (720.83 KB - PDF)
български (BG) (431.73 KB - PDF)
español (ES) (558.31 KB - PDF)
čeština (CS) (610.22 KB - PDF)
dansk (DA) (560.46 KB - PDF)
Deutsch (DE) (562.4 KB - PDF)
eesti keel (ET) (557.77 KB - PDF)
ελληνικά (EL) (706.33 KB - PDF)
français (FR) (582.58 KB - PDF)
italiano (IT) (562.61 KB - PDF)
latviešu valoda (LV) (639.76 KB - PDF)
lietuvių kalba (LT) (590.52 KB - PDF)
magyar (HU) (611.12 KB - PDF)
Malti (MT) (660 KB - PDF)
Nederlands (NL) (558.55 KB - PDF)
polski (PL) (620.09 KB - PDF)
português (PT) (559.21 KB - PDF)
română (RO) (588.46 KB - PDF)
slovenčina (SK) (616.19 KB - PDF)
slovenščina (SL) (497.45 KB - PDF)
Suomi (FI) (560.01 KB - PDF)
svenska (SV) (558.39 KB - PDF)
Product information
Rilonacept Regeneron : EPAR - Product Information
English (EN) (493.5 KB - PDF)
български (BG) (1.47 MB - PDF)
español (ES) (773.42 KB - PDF)
čeština (CS) (1.14 MB - PDF)
dansk (DA) (787.15 KB - PDF)
Deutsch (DE) (779.06 KB - PDF)
eesti keel (ET) (745.84 KB - PDF)
ελληνικά (EL) (1.61 MB - PDF)
français (FR) (807.27 KB - PDF)
íslenska (IS) (485.37 KB - PDF)
italiano (IT) (754.21 KB - PDF)
latviešu valoda (LV) (1.25 MB - PDF)
lietuvių kalba (LT) (1.03 MB - PDF)
magyar (HU) (1.19 MB - PDF)
Malti (MT) (1.14 MB - PDF)
Nederlands (NL) (771.71 KB - PDF)
norsk (NO) (521.03 KB - PDF)
polski (PL) (1.21 MB - PDF)
português (PT) (800.2 KB - PDF)
română (RO) (1018.64 KB - PDF)
slovenčina (SK) (1.1 MB - PDF)
slovenščina (SL) (1.12 MB - PDF)
Suomi (FI) (808.8 KB - PDF)
svenska (SV) (777.01 KB - PDF)
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Rilonacept Regeneron: EPAR - All Authorised presentations
English (EN) (217.77 KB - PDF)
български (BG) (308.08 KB - PDF)
español (ES) (431.7 KB - PDF)
čeština (CS) (509.78 KB - PDF)
dansk (DA) (431.7 KB - PDF)
Deutsch (DE) (472.64 KB - PDF)
eesti keel (ET) (431.7 KB - PDF)
ελληνικά (EL) (515.27 KB - PDF)
français (FR) (431.9 KB - PDF)
italiano (IT) (431.17 KB - PDF)
latviešu valoda (LV) (511.32 KB - PDF)
lietuvių kalba (LT) (498.69 KB - PDF)
magyar (HU) (509.98 KB - PDF)
Malti (MT) (512.66 KB - PDF)
Nederlands (NL) (431.33 KB - PDF)
polski (PL) (514.07 KB - PDF)
português (PT) (431.94 KB - PDF)
română (RO) (497.95 KB - PDF)
slovenčina (SK) (510.77 KB - PDF)
slovenščina (SL) (476.32 KB - PDF)
Suomi (FI) (431.55 KB - PDF)
svenska (SV) (432.23 KB - PDF)
Rilonacept Regeneron: EPAR - Conditions imposed on member states for safe and effective use - Annex IV
English (EN) (117.54 KB - PDF)
български (BG) (384.73 KB - PDF)
español (ES) (294.12 KB - PDF)
čeština (CS) (364.49 KB - PDF)
dansk (DA) (250.98 KB - PDF)
Deutsch (DE) (296.06 KB - PDF)
eesti keel (ET) (291.4 KB - PDF)
ελληνικά (EL) (317.47 KB - PDF)
français (FR) (250.84 KB - PDF)
italiano (IT) (292.89 KB - PDF)
latviešu valoda (LV) (371.02 KB - PDF)
lietuvių kalba (LT) (354.89 KB - PDF)
magyar (HU) (295.96 KB - PDF)
Malti (MT) (311.88 KB - PDF)
Nederlands (NL) (296.29 KB - PDF)
polski (PL) (309.36 KB - PDF)
português (PT) (310.3 KB - PDF)
română (RO) (357.59 KB - PDF)
slovenčina (SK) (309.75 KB - PDF)
slovenščina (SL) (301.29 KB - PDF)
Suomi (FI) (292.15 KB - PDF)
svenska (SV) (250.29 KB - PDF)
Product details
- Name of medicine
- Rilonacept Regeneron (previously Arcalyst)
- Active substance
- Rilonacept
- International non-proprietary name (INN) or common name
- rilonacept
- Therapeutic area (MeSH)
- Cryopyrin-Associated Periodic Syndromes
- Anatomical therapeutic chemical (ATC) code
- L04AC08
Pharmacotherapeutic group
ImmunosuppressantsTherapeutic indication
Rilonacept Regeneron is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) with severe symptoms, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), in adults and children aged 12 years and older.
Authorisation details
- EMA product number
- EMEA/H/C/001047
Exceptional circumstances
This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance.
- Marketing authorisation holder
- Regeneron UK Limited
40 Bank Street
London
E14 5DS
United Kingdom - Marketing authorisation issued
- 23/10/2009
- Revision
- 5
Assessment history
Rilonacept Regeneron : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (287.01 KB - PDF)
CHMP post-authorisation summary of positive opinion for Arcalyst
English (EN) (76.79 KB - PDF)
Rilonacept Regeneron : EPAR - Public assessment report
English (EN) (2.33 MB - PDF)
More information on Rilonacept Regeneron
Public statement on Rilonacept Regeneron: Withdrawal of the marketing authorisation in the European Union
English (EN) (48.05 KB - PDF)
This product was originally designated an orphan medicine on 10 July 2007. Rilonacept Regeneron was withdrawn from the Community register of orphan medicinal products by the European Commission in October 2012 at the time of the withdrawal of the marketing authorisation.